Semaglutide vs Tirzepatide: How They Differ

Semaglutide and tirzepatide are the two names driving most of the current GLP-1 conversation, and people constantly ask how they differ. This is a neutral, factual comparison — mechanism, brand names, approval status, and how they’re dosed. It deliberately does not say which is "better," because that is an individual medical decision that depends on your health, your history, and your doctor’s judgment. Both are prescription medications. This page is educational only and not medical advice; which (if either) is right for you is a conversation with your physician.

At a glance

	Semaglutide	Tirzepatide
Mechanism	GLP-1 receptor agonist (single pathway)	Dual GIP + GLP-1 receptor agonist (two pathways)
Common brand names	Ozempic, Wegovy (injection); Rybelsus (oral)	Mounjaro, Zepbound (injection)
FDA status	FDA-approved	FDA-approved
Typical schedule	Once weekly injection (Rybelsus is a daily tablet)	Once weekly injection
Started	Dose is individualized and adjusted over time by a prescriber	Dose is individualized and adjusted over time by a prescriber

Specific doses are intentionally omitted here because they are individualized and set by a prescriber — this page compares the medicines, not what anyone should take.

The core mechanistic difference

The headline distinction is how many hormone pathways each one acts on:

Semaglutide is a GLP-1 receptor agonist — it mimics one gut hormone (GLP-1) involved in appetite and blood-sugar regulation.
Tirzepatide is a dual agonist — it acts on both GLP-1 and a second hormone receptor, GIP. This "twincretin" action is what makes it mechanistically distinct.

What that difference means for any specific person — effectiveness, side effects, suitability — varies individually and is exactly the kind of thing a prescriber weighs. It is not something a web page (or an app) can decide for you.

Brand names and forms

Both compounds are sold under different brand names for different approved uses:

Semaglutide — marketed as Ozempic and Wegovy as injections, and as Rybelsus in an oral tablet form. (As of 2026, the first generic semaglutide has launched in some countries outside the U.S., but there is no FDA-approved U.S. generic.)
Tirzepatide — marketed as Mounjaro and Zepbound.

Same active compound can appear under more than one brand depending on the approved indication — which is why the generic name matters more than the brand when you’re keeping records.

What they have in common

Both are FDA-approved prescription medicines — not something to obtain or self-select outside a doctor’s care.
Both injectable forms are typically once weekly.
Both are generally started low and adjusted over time under a prescriber’s plan to manage tolerability.
Both belong to the broader class often discussed as "GLP-1 medicines," even though tirzepatide adds the GIP pathway.

The honest bottom line

The factual differences are clear: one pathway vs two, different brand names, both FDA-approved, both usually weekly. Which one — if either — fits a given person is not a decision this page will make, because it depends on individual medical factors only a physician can weigh. Anyone comparing these should do it with their doctor, and should be cautious of any source that pushes one over the other or offers either without a prescription.

Where Pepathary fits

Pepathary doesn’t recommend or compare treatments for you. What it does is help you organize whatever your doctor prescribed — the weekly schedule, reminders, a log of what you took and how you felt, and (for injections that require it) the reconstitution math. It never suggests a medication or a dose.

Organize whatever your doctor prescribes

Pepathary tracks schedules and reminders for the medication you and your doctor chose. It does not recommend or compare treatments for you.

Open the free calculator Open Pepathary (free)

Common questions

Is tirzepatide just a stronger semaglutide?

No — they are different molecules. Semaglutide acts on the GLP-1 receptor alone, while tirzepatide is a dual agonist acting on both GLP-1 and GIP receptors. Whether that difference matters for a specific person is an individual medical question for a prescriber, and this page does not rank one above the other.

What are the brand names for each?

Semaglutide is sold as Ozempic and Wegovy (injections) and Rybelsus (oral tablet). Tirzepatide is sold as Mounjaro and Zepbound. The same active compound can carry different brand names for different approved uses.

Are both FDA-approved?

Yes. Both semaglutide and tirzepatide are FDA-approved prescription medications. They should be used under a doctor’s care with a prescription, not selected or obtained on your own.

How often are they injected?

Both injectable forms are typically taken once weekly. Semaglutide also has an oral tablet form (Rybelsus) taken daily. Exact dosing is individualized and set by a prescriber.

Which one should I take?

That is a medical decision only your physician can make with you, based on your health and history. This page compares the medicines factually but intentionally does not recommend one over the other, and Pepathary does not either.